Drug Profile
Peptide-based blood coagulant - Haemostatix
Alternative Names: Haemostasis therapeutic - Haemostatix; Haemostat topical - Haemostatix; PeproStat; PeproStat Liquid; Peptide-based antihaemorrhagic - HaemostatixLatest Information Update: 11 Aug 2021
Price :
$50
*
At a glance
- Originator Haemostatix
- Developer Boryung Pharmaceutical; Haemostatix
- Class Antihaemorrhagics; Peptides
- Mechanism of Action Fibrin stimulants; Fibrinogen modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Surgical blood loss
Most Recent Events
- 10 Aug 2021 Phase-II clinical trials in Surgical blood loss in South Korea (Topical, Liquid) (Boryung Pharmaceutical pipeline, August 2021)
- 05 Mar 2021 No development reported - Phase-II for Surgical blood loss (Prevention) in Serbia, United Kingdom, Croatia, Bosnia-Herzegovina, Poland (Topical)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Surgical-blood-loss(Prevention) in United Kingdom (Topical, Paste)